文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Prophylactic surgical ligation of patent ductus arteriosus for prevention of mortality and morbidity in extremely low birth weight infants.

作者信息

Mosalli R, Alfaleh K

机构信息

McMaster University Medical Centre, Pediatrics, Division of Neonatology, 1200 Main Street West, Hamilton, Ontario, Canada, L8N 3Z5.

出版信息

Cochrane Database Syst Rev. 2008 Jan 23;2008(1):CD006181. doi: 10.1002/14651858.CD006181.pub2.


DOI:10.1002/14651858.CD006181.pub2
PMID:18254095
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8916218/
Abstract

BACKGROUND: Patent ductus arteriosus (PDA) is associated with increased mortality and morbidity in preterm infants. Prophylactic indomethacin results in favorable intermediate outcomes such as reduction of significant PDA, need for surgical ligation, severe intraventricular hemorrhage and serious pulmonary hemorrhage without modifying long-term neurosensory outcomes. Little is known about the effectiveness and safety of prophylactic surgical closure of the PDA in extremely low birth weight (ELBW) infants. OBJECTIVES: To identify and summarize evidence from randomized controlled trials investigating the effectiveness and safety of prophylactic surgical ligation of the PDA on mortality and morbidities of preterm infants less than 1000 g at birth as compared to no prophylaxis or prophylactic cyclooxygenase inhibitors. SEARCH STRATEGY: The standard search strategy for the Cochrane Neonatal Review Group was performed by two review authors. Searches were made of MEDLINE (1966 to December 2006), EMBASE (1980 to December 2006), the Cochrane Central Register of Controlled Trials (The Cochrane Library, Issue 4, 2006), and abstracts of annual meetings of the Society for Pediatric Research (1995 - 2006). Contacts were made with the authors of published articles. SELECTION CRITERIA: Randomized or quazi-randomized controlled trials that enrolled infants less than 28 weeks gestation or less than 1000 g at birth who are on assisted ventilation and/or supplemental oxygen without clinical signs of hemodynamic significance of the ductus arteriosus were considered. Trials addressing prophylactic surgical ligation of the patent ducts arteriosus (i.e. procedure done during the first 72 hours of life) versus no intervention or cyclooxygenase inhibitor prophylaxis were included. The primary outcome was bronchopulmonary dysplasia (BPD). Other important short and long-term neonatal outcomes were also considered. DATA COLLECTION AND ANALYSIS: Standard methods of the Cochrane Collaboration and its Neonatal Review Group were used to assess the methodologic quality of the trials. Retrieved articles were assessed for eligibility and data was abstracted independently by two reviewer authors. Where data were incomplete, the primary investigators were contacted for further information and clarifications. For dichotomous outcomes, relative risk (RR) and its associated confidence interval were calculated. For continuous outcomes, treatment effect was expressed as mean difference and its calculated standard deviation. When appropriate, meta-analysis of pooled data was performed assuming a fixed effect model MAIN RESULTS: Only one eligible study that enrolled 84 ELBW infants was identified. The prophylactic group had ductal ligation performed within 24 hours of life following a pre-specified protocol, while the control group received standard care without indomethacin. Prophylactic surgical ligation of the PDA resulted in a statistically significant reduction of severe stage II or III necrotizing enterocolitis (NEC), [RR 0.25, 95% CI (0.08,0.83), p value 0.02, NNT 5]. The study found no statistically significant difference in mortality, severe grade III and IV intraventricular hemorrhage (IVH), BPD, and retinopathy of prematurity (ROP). Of note, the study was unblinded and underpowered to detect clinically important differences in the above mentioned outcomes. AUTHORS' CONCLUSIONS: Prophylactic surgical ligation of the PDA did not decrease mortality or BPD in ELBW infants. A significant reduction of stage II or III NEC was noted. Based on the current evidence, the high rate of spontaneous closure, availability of effective safe medical therapies, and the potential short and long-term complications of surgical ligation, the use such prophylactic surgical therapy is not indicated in the management of the preterm infants.

摘要

相似文献

[1]
Prophylactic surgical ligation of patent ductus arteriosus for prevention of mortality and morbidity in extremely low birth weight infants.

Cochrane Database Syst Rev. 2008-1-23

[2]
Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants.

Cochrane Database Syst Rev. 2008-1-23

[3]
Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants.

Cochrane Database Syst Rev. 2005-10-19

[4]
Ibuprofen for the treatment of a patent ductus arteriosus in preterm and/or low birth weight infants.

Cochrane Database Syst Rev. 2003

[5]
Prolonged versus short course of indomethacin for the treatment of patent ductus arteriosus in preterm infants.

Cochrane Database Syst Rev. 2007-4-18

[6]
Surgical versus medical treatment with cyclooxygenase inhibitors for symptomatic patent ductus arteriosus in preterm infants.

Cochrane Database Syst Rev. 2008-1-23

[7]
Paracetamol (acetaminophen) for patent ductus arteriosus in preterm or low birth weight infants.

Cochrane Database Syst Rev. 2022-12-15

[8]
Continuous infusion versus intermittent bolus doses of indomethacin for patent ductus arteriosus closure in symptomatic preterm infants.

Cochrane Database Syst Rev. 2008-1-23

[9]
Ibuprofen for the prevention of patent ductus arteriosus in preterm and/or low birth weight infants.

Cochrane Database Syst Rev. 2006-1-25

[10]
Prolonged versus short course of indomethacin for the treatment of patent ductus arteriosus in preterm infants.

Cochrane Database Syst Rev. 2004

引用本文的文献

[1]
Closing the Gap: Investigation of Various Approaches in the Management of Patent Ductus Arteriosus.

Cureus. 2023-9-11

[2]
Nutrition of the preterm infant with persistent ductus arteriosus: existing evidence and practical implications.

Pediatr Res. 2023-8-10

[3]
Interventions for patent ductus arteriosus (PDA) in preterm infants: an overview of Cochrane Systematic Reviews.

Cochrane Database Syst Rev. 2023-4-11

[4]
Patent Ductus Arteriosus: A Contemporary Perspective for the Pediatric and Adult Cardiac Care Provider.

J Am Heart Assoc. 2022-9-6

[5]
Development and Validation of a Nomogram for Predicting the Risk of Bell's Stage II/III Necrotizing Enterocolitis in Neonates Compared to Bell's Stage I.

Front Pediatr. 2022-6-14

[6]
Patent ductus arteriosus treatment trends and associated morbidities in neonates.

Sci Rep. 2021-5-21

[7]
Predictive Model of Early Spontaneous Ductus Arteriosus Closure Based on Neonatologist Performed Echocardiography in Preterm Infants.

Front Pediatr. 2021-2-26

[8]
Echocardiographic Diagnosis and Hemodynamic Evaluation of Patent Ductus Arteriosus in Extremely Low Gestational Age Newborn (ELGAN) Infants.

Front Pediatr. 2020-11-19

[9]
Patent Ductus Arteriosus of the Preterm Infant.

Pediatrics. 2020-11

[10]
Transcatheter Closure of Patent Ductus Arteriosus in Infants With Weight Under 1,500 Grams.

Front Pediatr. 2020-9-22

本文引用的文献

[1]
Prevention and 18-month outcomes of serious pulmonary hemorrhage in extremely low birth weight infants: results from the trial of indomethacin prophylaxis in preterms.

Pediatrics. 2008-2

[2]
Neurosensory impairment after surgical closure of patent ductus arteriosus in extremely low birth weight infants: results from the Trial of Indomethacin Prophylaxis in Preterms.

J Pediatr. 2007-3

[3]
Treatment strategies to prevent or close a patent ductus arteriosus in preterm infants and outcomes.

J Perinatol. 2007-3

[4]
Enhanced intensive care for the neonatal ductus arteriosus.

Acta Paediatr. 2006-4

[5]
Patency of the ductus arteriosus in the premature infant: is it pathologic? Should it be treated?

Curr Opin Pediatr. 2004-4

[6]
Effect of early targeted indomethacin on the ductus arteriosus and blood flow to the upper body and brain in the preterm infant.

Arch Dis Child Fetal Neonatal Ed. 2003-11

[7]
Surgical versus medical treatment with cyclooxygenase inhibitors for symptomatic patent ductus arteriosus in preterm infants.

Cochrane Database Syst Rev. 2003

[8]
Hemodynamic and antecedent risk factors of early and late periventricular/intraventricular hemorrhage in premature infants.

Pediatrics. 2003-7

[9]
Bronchopulmonary dysplasia: changes in pathogenesis, epidemiology and definition.

Semin Neonatol. 2003-2

[10]
Prophylactic intravenous indomethacin for preventing mortality and morbidity in preterm infants.

Cochrane Database Syst Rev. 2002

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索